Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches
Author
Thomas, N. J.
McGovern, A.
Young, K. G.
Sharp, S. A.
Weedon, M. N.
Hattersley, A. T.
Dennis, J.
Jones, A. G.
Date
2022-11-08Journal
Journal of clinical epidemiologyType
Journal ArticlePublisher
ElsevierDOI
10.1016/j.jclinepi.2022.10.022Rights
© 2022 The Author(s). Published by Elsevier Inc. All rights reserved.Metadata
Show full item recordAbstract
OBJECTIVE: We aimed to compare the performance of approaches for classifying insulin treated diabetes within research datasets without measured classification biomarkers, evaluated against two independent biological definitions of diabetes type. STUDY DESIGN AND SETTING: We compared accuracy of ten reported approaches for classifying insulin treated diabetes into type 1 (T1D) and type 2 (T2D) diabetes in two cohorts: UK Biobank (UKBB) n=26,399 and DARE n=1,296. Overall performance for classifying T1D and T2D were assessed using: a T1D genetic risk score and genetic stratification method (UKBB); C-peptide measured at >3 years diabetes duration (DARE). RESULTS: Approaches accuracy ranged from 71%-88% (UKBB) and 68%-88% (DARE). When classifying all participants, combining early insulin requirement with a T1D probability model (incorporating diagnosis age and BMI), and interview reported diabetes type (UKBB available in only 15%) consistently achieved high accuracy, (UKBB 87% and 87%, DARE 85% and 88% respectively). For identifying T1D with minimal misclassification, models with high thresholds or young diagnosis age (<20 years) had highest performance. Findings were incorporated into an online tool identifying optimum approaches based on variable availability. CONCLUSION: Models combining continuous features with early insulin requirement are the most accurate methods for classifying insulin treated diabetes in research datasets without measured classification biomarkers.
Citation
J Clin Epidemiol. 2022 Nov 8:S0895-4356(22)00272-4. doi: 10.1016/j.jclinepi.2022.10.022.Note
The article is available via Open Access. Click on the 'Additional link' above to access the full-text.Collections
Except where otherwise noted, this item's license is described as © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Related items
Showing items related by title, author, creator and subject.
-
Systematic genetic testing for recessively inherited monogenic diabetes: a cross-sectional study in paediatric diabetes clinics
Patel, K. A.; Ozbek, M. N.; Yildiz, M.; Guran, T.; Kocyigit, C.; Acar, S.; Siklar, Z.; Atar, M.; Colclough, K.; Houghton, J.; Johnson, M. B.; Ellard, S.; Flanagan, S. E.; Cizmecioglu, F.; Berberoglu, M.; Demir, K.; Catli, G.; Bas, S.; Akcay, T.; Demirbilek, H.; Weedon, M. N.; Hattersley, A. T. (Springer, 2021-10-23)AIMS/HYPOTHESIS: Current clinical guidelines for childhood-onset monogenic diabetes outside infancy are mainly focused on identifying and testing for dominantly inherited, predominantly MODY genes. There are no systematic ... -
Unsupervised Clustering of Missense Variants in HNF1A Using Multidimensional Functional Data Aids Clinical Interpretation
Colclough, Kevin; Ellard, Sian (Elsevier Science, 2020-10-01)Exome sequencing in diabetes presents a diagnostic challenge because depending on frequency, functional impact, and genomic and environmental contexts, HNF1A variants can cause maturity-onset diabetes of the young (MODY), ... -
Evaluation of pregnancy outcomes in women with GCK-MODY
Colclough, Kevin (Wiley, 2021-06)Aims: To determine the fetal and maternal outcomes in pregnant women with Glucokinase-Maturity onset diabetes of the young (GCK-MODY). Methods: We studied the obstetric and perinatal outcomes in 99 pregnancies of 34 ...